Clinical Trial Detail

NCT ID NCT02864992
Title Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

lung adenocarcinoma

Therapies

Tepotinib

Age Groups: senior adult

Additional content available in CKB BOOST